In brief: Peplin, Bone Medical, Probiomics, BioDiem

By Helen Schuller
Monday, 01 August, 2005

Peplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

Bone Medical (ASX:BNE) has appointed BIO-IB as financial advisors to assist with a potential capital raise targeting US institutional investors expected to take place later this year.

Taylor Collison intends to underwrite a $1 million placement of new fully paid ordinary shares in Probiomics (ASX:PCC). A total of 12,500,000 shares will be issued at $0.08 per share and the funds from the placement will be used for working capital.

BioDiem (ASXBDM) has received its second US$1 million milestone payment under its US$8m licence agreement with Akzo Nobel's Nobilon in the development of its novel intranasal flu vaccine.

Related News

Link between oestrogen and heart health found in women

Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...

Frequent nightmares accelerate aging, increase risk of death

Nghtmares independently predict faster biological aging and earlier mortality — even after...

Cardiac organoids bring hope for treating heart disease

Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd